- Most Recent Funding
- $140M Debt Financing on June 29, 2016
In the short period since Iroko was founded in 2007, we have assembled a portfolio of proven pharmaceuticals, especially prescription pain medicines. Our goal has been to bring new life to these trusted products—new geographic markets, new indications, and new benefits through further development enabled by new technology.
We have already extended a distribution and sales network across more than 40 countries. And we have developed an industry-leading pipeline of nano-formulated lower-dose NSAIDs to address the need for new options in pain management.
Experience. Marketed products. A global presence. Innovation.
That’s Iroko. We’re an established company. And we’re hurrying to improve healthcare.
Funding Rounds (2) - $215MUpdate
Current Team (3)Update
Board Members and Advisors (2)Update
|Jun 29, 2016||iroko.com - Iroko Pharmaceuticals Secures Debt Financing From CRG|
|Jul 15, 2015||Business Wire - Iroko Pharmaceuticals Announces Eighth International Licensing Agreement for ZORVOLEX®|
|May 14, 2015||Business Wire - Iroko Pharmaceuticals Announces First International Launch of ZORVOLEX|
|May 14, 2015||Business Wire - Iroko Pharmaceuticals Announces First International Launch of ZORVOLEX®|
|May 6, 2015||Business Wire - Iroko Pharmaceuticals Announces Additional International Licensing Agreement for ZORVOLEX®|
|Nov 21, 2013||FinSMEs - FinSMEs|
|Jun 18, 2013||renaissancecapital.com - Iroko Pharmaceuticals files for a $145 million IPO|
One Kew Place
150 Rouse Boulevard
Philadelphia, Pennsylvania 19112